Tue, February 13, 2024
[ Tue, Feb 13th 2024
] - WOPRAI
Fri, December 8, 2023
[ Fri, Dec 08th 2023
] - WOPRAI
Wed, November 1, 2023
[ Wed, Nov 01st 2023
] - WOPRAI
Thu, October 26, 2023
Wed, August 30, 2023
[ Wed, Aug 30th 2023
] - WOPRAI
[ Wed, Aug 30th 2023
] - WOPRAI
Mon, August 21, 2023
[ Mon, Aug 21st 2023
] - WOPRAI
Fri, July 28, 2023
[ Fri, Jul 28th 2023
] - WOPRAI
Wed, July 12, 2023
Thu, May 25, 2023
[ Thu, May 25th 2023
] - WOPRAI
Wed, May 24, 2023
Wed, May 10, 2023
Fri, May 5, 2023
[ Fri, May 05th 2023
] - WOPRAI
Tue, March 14, 2023
[ Tue, Mar 14th 2023
] - WOPRAI
Fri, March 3, 2023
[ Fri, Mar 03rd 2023
] - WOPRAI
Fri, February 17, 2023
[ Fri, Feb 17th 2023
] - WOPRAI
Fri, February 3, 2023
[ Fri, Feb 03rd 2023
] - WOPRAI
Fri, December 2, 2022
[ Fri, Dec 02nd 2022
] - WOPRAI
Tue, November 22, 2022
[ Tue, Nov 22nd 2022
] - WOPRAI
Fri, October 28, 2022
[ Fri, Oct 28th 2022
] - WOPRAI
Mon, October 24, 2022
[ Mon, Oct 24th 2022
] - WOPRAI
Thu, September 15, 2022
[ Thu, Sep 15th 2022
] - WOPRAI
Thu, June 2, 2022
[ Thu, Jun 02nd 2022
] - WOPRAI
Fri, May 13, 2022
[ Fri, May 13th 2022
] - WOPRAI
Wed, May 11, 2022
[ Wed, May 11th 2022
] - WOPRAI
Tue, May 10, 2022
[ Tue, May 10th 2022
] - WOPRAI
[ Tue, May 10th 2022
] - WOPRAI
Thu, May 5, 2022
[ Thu, May 05th 2022
] - WOPRAI
Fri, April 29, 2022
[ Fri, Apr 29th 2022
] - WOPRAI
Fri, March 25, 2022
[ Fri, Mar 25th 2022
] - WOPRAI
Paul Knight Maintained (WST) at Buy with Increased Target to $470 on, Feb 13th, 2024
Paul Knight of Keybanc, Maintained "West Pharmaceutical Services, Inc." (WST) at Buy with Increased Target from $440 to $470 on, Feb 13th, 2024.
Paul has made no other calls on WST in the last 4 months.
There are 2 other peers that have a rating on WST. Out of the 2 peers that are also analyzing WST, 0 agree with Paul's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Paul
- David Windley of "Jefferies" Upgraded from Hold to Strong Buy and Increased Target to $536 on, Wednesday, February 7th, 2024
- Jacob Johnson of "Stephens & Co." Maintained at Buy with Decreased Target to $390 on, Friday, October 27th, 2023
Contributing Sources